The present result that TNF-α promotes eosinophil survival and thus may contribute to eosinophilia especially in asthma or COPD exacerbations gives further support to the view [8] that anti-TNF-α therapies should not be completely abandoned and may be better targeted to the phenotype of asthmatics with high eosinophilia. The gene discussed is TNF; the disease is asthma.